Global Cellular Immunotherapy Market Report 2020-2030: COVID-19 Impact and Forecast

Strategic Insights -

The global cellular immunotherapy market experienced a decline in 2020 due to the COVID-19 pandemic, with a CAGR of -5.90% and a revenue of $2.74 billion. However, the market is expected to recover and reach $5.05 billion in 2023, with a CAGR of 22.53%. The market is driven by increasing research and successful clinical trials in cellular immunotherapy, with companies focusing on developing off-the-shelf allogeneic therapies for new and improved cancer treatment.

Key Takeaways:

  • The global cellular immunotherapy market is expected to decline to $2.74 billion in 2020, a decrease of -5.90% from $2.92 billion in 2019.
  • The market is expected to recover and reach $5.05 billion in 2023, a growth of 22.53% from $4.13 billion in 2022.
  • The high cost of cellular immunotherapies, particularly CAR-T therapy, is a significant restraint on the market, with prices exceeding $350,000 per treatment in the USA.
  • Companies in the cellular immunotherapy market are focusing on developing off-the-shelf allogeneic therapies, which offer advantages such as cost-effectiveness, large-scale production, and fast and quality-controlled production.
  • The market is expected to drive the growth of the cellular immunotherapy market, with companies such as Novartis AG, Gilead Sciences Inc. (Kite Pharma), and Apac Biotech leading the way.
  • The global cellular immunotherapy market is segmented by therapy, primary indication, and application, with the tumor-infiltrating lymphocyte (TIL) therapy segment expected to experience significant growth.
  • Key players in the market, including ResTORbio and Adicet Bio, are working together to advance allogeneic gamma-delta CAR-T cell therapy technology.

Statistics:

  • Global cellular immunotherapy market size: $2.74 billion (2020), expected to reach $5.05 billion (2023).
  • CAGR: -5.90% (2020), 22.53% (2023-2030).
  • Number of cellular immunotherapy products approved in the USA: 2 (as of 2020).
  • Price of Yescarta and Kymriah per treatment in the USA: over $350,000.
  • Number of companies focused on developing off-the-shelf allogeneic therapies: 10+.

Sources:

  • M2 PressWIRE, "Global Cellular Immunotherapy Market Report 2020-2030 (C)1994-2021 M2 COMMUNICATIONS RDATE:21012021"
  • ResearchAndMarkets.com, "Cellular Immunotherapy Global Market Report 2020-30: COVID-19 Growth and Change"